TWSI yields 3448.28% · ABBV yields 3.06%● Live data
📍 TWSI pulled ahead of the other in Year 1
Combined, TWSI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TWSI + ABBV for your $10,000?
TriStar Wellness Solutions, Inc. develops, markets, and sells wound care products. The company also offers skincare and other products under the Beaute de Maman name for pregnant and nursing women; bleeding and wound management products for surgical, health care, consumer, and military markets; and develops and markets Delivery Devise with Invertible Diaphragm, which is a medical applicator for delivering medicants and internal devices within the body without producing injury or damage. In addition, it develops over-the-counter itch suppression products; and develops, manufactures, and markets wound care and infection control medical devices. The company was formerly known as BioPack Environmental Solutions, Inc. and changed its name to TriStar Wellness Solutions, Inc. in January 2013. TriStar Wellness Solutions, Inc. is based in Portland, Oregon. On January 15, 2016, TriStar Wellness Solutions, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Oregon.
Full TWSI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.